Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years by Andreas Wollenberg, Masanori Ikeda, Chia-Yu Chu, Lawrence F. Eichenfield, Marieke M. B. Seyger, Apurva Prakash, Robinette Angle, Danting Zhu, Marco Pontes, Amy S. Paller

Get full text

Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 an... by Jonathan I. Silverberg, Melinda Gooderham, Norito Katoh, Valeria Aoki, Andrew E. Pink, Yousef Binamer, Brad Glick, Petra Staubach, Brian Calimlim, Chao Li, Ayman Grada, Alvaro Moreira, Wan-Ju Lee, Andreas Wollenberg

Get full text

Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic Dermatitis by Jonathan I. Silverberg, Melinda Gooderham, Andreas Wollenberg, Andrew E. Pink, Diego Ruiz Dasilva, Shawn G. Kwatra, Yousef Binamer, Norito Katoh, Valeria Aoki, Alvaro Moreira, Ayman Grada, Chao Li, Brian Calimlim, Wan-Ju Lee, Christopher G. Bunick

Get full text